Phases, active trials: Phase 1: 11, Phase 2: 56, Phase 3: 53, Other: 57
Sanofi and Regeneron operate an extensive co-development partnership spanning immunology, oncology, and rare disease. Dupixent (dupilumab), the IL-4Rα-blocking antibody, is the fastest-growing biologic in history, and Sanofi continues expanding its label into new type-2 inflammatory conditions (COPD, prurigo nodularis, alopecia areata). Their shared oncology pipeline includes cemiplimab (Libtayo), the PD-1 inhibitor with approvals in skin cancers and NSCLC, plus a broad REGN antibody program in hematology and solid tumors. Sanofi's rare disease heritage (Gaucher, Pompe, Fabry) continues with next-generation enzyme replacement therapies and gene therapies.
- Type-2 inflammation / allergy (IL-4Rα, IL-33, TSLP)
- Oncology (PD-1, bispecifics, hematology)
- Rare / metabolic disease (lysosomal storage, hemophilia)
- Neurology
- Vaccines (Beyfortus RSV)
- Dupixent (dupilumab): IL-4Rα, atopic dermatitis/asthma/COPD
- Libtayo (cemiplimab): PD-1, skin cancers/NSCLC
- Sarclisa (isatuximab): anti-CD38, multiple myeloma
- Zynquista (sotagliflozin): SGLT1/2, T1D/heart failure
- REGN5458: BCMAxCD3 bispecific, myeloma
- Fitusiran: RNAi-based hemophilia therapy
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| International Treatment-extension Study in Adult Participants With Multiple… NCT05669989 | Primary completion moved at least 2 years later | Enrolling by Invitation |
11 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab… NCT06834347 | Oct 14, 2026 · Estimated | Phase 3 |
18 more on the Completions page. See the calendar →
Monitor the Sanofi / Regeneron pipeline daily
Get a daily digest when Sanofi / Regeneron registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Healthy Volunteers | 18 |
| Atopic Dermatitis | 7 |
| Dermatitis Atopic | 7 |
| Asthma | 5 |
| Chronic Graft Versus Host Disease | 5 |
| Crohn's Disease | 5 |
| Glycogen Storage Disease Type II | 5 |
| Pneumococcal Immunization | 5 |
Dupixent's label expansion program generates consistent new trial registrations across type-2 inflammatory conditions. Any company developing IL-4, IL-13, IL-33, or TSLP-targeted therapies needs to monitor Sanofi/Regeneron's trial activity closely.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Sanofi / Regeneron's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Sanofi / Regeneron may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Sanofi / Regeneron pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study Evaluating Disease Characteristics and Outcomes in Participants With… NCT07556159 | Recruiting | Trial sites expanded: 62 → 71 locations | 2026-10-10 |
| Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With… NCT06052800 | Active, Not Recruiting | Completion pushed from Sep 10, 2026 to Nov 6, 2026 | 2026-10-09 |
| Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in… NCT07348692 | Recruiting | Trial sites expanded: 19 → 25 locations | 2026-10-06 |
| A Study to Investigate the Efficacy and Safety of Brivekimig in Adult… NCT06975722 | Active, Not Recruiting | Enrollment closed, study ongoing | 2026-10-03 |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in… NCT07190222 | Recruiting | Trial sites expanded: 214 → 315 locations | 2026-10-02 |
Each trial page shows every change DataLookout has recorded for that trial.